Benzinga · Feb 25, 2026
EN
NASDAQ · ENVB
Enveric Biosciences, Inc.
Healthcare · Biotechnology
$1.46
Down-$0.04 (-2.67%)
Updated Nov 5, 2026, 5:21 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.25M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.17 – $13.25
- Volume
- 35.77K
- Avg. volume
- 85.35K
Price performance · ENVB
ENVB price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
ENVB closed at $1.46 after 21 trading sessions, down 2.34% for the selected period.
- Last close
- $1.46
- Period change
- -2.34%
- Period low
- $1.37
- Period high
- $1.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.58 | $1.58 | $1.43 | $1.46 | 35.77K |
| Nov 3, 2026 | $1.45 | $1.51 | $1.41 | $1.50 | 43.27K |
| Nov 2, 2026 | $1.41 | $1.54 | $1.41 | $1.45 | 28.4K |
| Oct 30, 2026 | $1.47 | $1.495 | $1.40 | $1.43 | 12K |
| Oct 29, 2026 | $1.43 | $1.49 | $1.42 | $1.46 | 29.47K |
| Oct 28, 2026 | $1.44 | $1.489 | $1.3802 | $1.47 | 21.22K |
| Oct 27, 2026 | $1.3561 | $1.45 | $1.3561 | $1.42 | 56.49K |
| Oct 26, 2026 | $1.37 | $1.41 | $1.30 | $1.38 | 30.58K |
| Oct 23, 2026 | $1.44 | $1.505 | $1.39 | $1.40 | 33.35K |
| Oct 22, 2026 | $1.51 | $1.57 | $1.44 | $1.46 | 35.13K |
| Oct 21, 2026 | $1.465 | $1.5882 | $1.4301 | $1.51 | 84.52K |
| Oct 20, 2026 | $1.375 | $1.445 | $1.375 | $1.44 | 31.41K |
| Oct 19, 2026 | $1.38 | $1.425 | $1.36 | $1.39 | 31.54K |
| Oct 16, 2026 | $1.35 | $1.4423 | $1.35 | $1.38 | 22.53K |
| Oct 15, 2026 | $1.37 | $1.438 | $1.35 | $1.39 | 21.21K |
| Oct 14, 2026 | $1.38 | $1.45 | $1.33 | $1.37 | 163.91K |
| Oct 13, 2026 | $1.43 | $1.49 | $1.38 | $1.40 | 102.07K |
| Oct 12, 2026 | $1.43 | $1.5199 | $1.40 | $1.47 | 114.68K |
| Oct 9, 2026 | $1.48 | $1.495 | $1.44 | $1.45 | 50.25K |
| Oct 8, 2026 | $1.47 | $1.5309 | $1.46 | $1.52 | 64.87K |
| Oct 7, 2026 | $1.45 | $1.5099 | $1.45 | $1.495 | 41.37K |
Latest ENVB news
The latest Smart Investors Daily articles mentioning ENVB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ENVB research
Overview
Company profile and research snapshot.
Company profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 6, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 1, 2022 | Alliance Global Partners | Buy | — |
| Mar 8, 2022 | Aegis Capital | Hold | — |
| Jul 8, 2021 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested
Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.
Benzinga · Feb 25, 2026
Enveric Biosciences Announces Withdrawal Of Petition Against Patent; Co Says There Are 'No Remaining Challenges' Pending Against Patent
Benzinga · Feb 19, 2026
Enveric Biosciences shares are trading higher after the company announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
